Law & the Courts

The Extortion of Big Pharma

A medic escorts a 39-year-old woman to an ambulance after she was revived from an opioid overdose in Salem, Mass., August 2017. (Brian Snyder/Reuters)
President Trump has proposed suing the drug industry over its role in the opioid crisis. Like most such suits, this one would be an opportunistic cash grab.

To Donald Trump, it seems, capitalism is less a matter of the market’s “invisible hand” than of his own presidential hand on the economic scales. Mr. Trump’s threat last week to bring a “major” lawsuit against pharmaceutical companies that produce FDA-approved pain medications not only tips the scale against Big Pharma, but undermines the rule of law.

A federal lawsuit would not, of course, be the first government case against the makers of prescription opioids. In 2014, Chicago and two California counties became the first government entities to sue the drug companies for the public costs of the opioid-abuse crisis. Since then, hundreds of cities, counties, states, and Native American tribes have jumped on the bandwagon looking for big payouts from the drug industry. Today, there are close to 1,000 opioid-related cases pending in courts across the country, hundreds of which have been consolidated before a single judge in Ohio.

The government plaintiffs seek billions of dollars in damages, purportedly to pay for the uptick in public spending on law enforcement, prisons, treatment, and social-welfare programs since the beginning of the opioid crisis.

Such lawsuits are a form of legalized extortion.

Countless legal products and private activities contribute to increases in government spending. Will the government next sue Anheuser-Busch for the economic costs of alcoholism? Can a case against Ford and GM to recoup the public cost of car accidents be far behind?

Spending money to address societal ills, both old and new, is what governments do. Suing companies into paying for public costs associated with the misuse of their products is a government shakedown.

Unfortunately, this abuse of our legal system is nothing new.

Government opioid lawsuits mirror the tobacco cases of the 1990s, in which 46 states sued cigarette makers for the public cost of smoking-related diseases. Not surprisingly, many of the state and local jurisdictions currently suing Big Pharma have hired the same plaintiff attorneys who made a fortune off the tobacco settlements.

The arguments made by the states against cigarette makers were legally weak. But to avoid infinite litigation, tobacco companies entered into a master settlement agreement that required them to pay hundreds of billions of dollars to the states.

The enormity of the tobacco settlement has incentivized plaintiff attorneys and cash-strapped governments to sue other unpopular companies in hopes of an equally big payday. The suits against Big Pharma have even less validity than those against Big Tobacco. Unlike cigarettes, which cause harm even when used as intended, opioids can be highly beneficial medicines when used as prescribed. In fact, studies show that only a tiny fraction of people prescribed opioids become addicted; the overwhelming majority of patients are helped by the medicines.

But Mr. Trump and the politicians already suing the industry don’t care whether the cases have legal merit. They are playing a different game: making the cost of defending such lawsuits so exorbitant and unpredictable that the industry has little choice other than to settle.

For politicians, litigation is win-win: If it’s successful, it funds government largesse without raising taxes. If it fails, it still generates fawning publicity for politicians who “stand up” to the latest boogeyman.

What it won’t do, however, is solve the crisis.

After thousands of private attorneys take their cut of any settlement money, the government plaintiffs will no doubt apply the remaining funds to budget shortfalls or use them for pet projects. This is precisely what happened with the tobacco settlements: Only a tiny fraction of the billions of dollars that tobacco companies paid to state governments went to reduce cigarette smoking.

Ultimately, it is the consumer who bears the costs of these lawsuits in the form of higher drug prices, reduced access to pain medications for patients who need them, and less funding for the research and development of new medications and cures.

What’s more, these suits hurt our democracy. The constitutional doctrine of separation of powers mandates that courts stay out of the public-policy arena in deference to the political branches of government. It is the job of the legislative and executive branches to pass laws and regulations regarding the manufacture and distribution of prescription medications. Congress and the FDA are responsible for collecting relevant data and weighing the interests of various stakeholders before determining how best to regulate such drugs. The Department of Justice is responsible for prosecuting those who break the law by, for example, diverting prescription medications to the black market.

Courts, by contrast, are ill-equipped to weigh the costs and benefits of legal medications, develop federal drug-control policy, or impose new rules on the makers of prescription medications. But that is exactly what these lawsuits ask them to do.

Thankfully, some courts are starting to push back against regulation-by-litigation. In June, a federal district court in California rejected a similar lawsuit by the cities of San Francisco and Oakland against Exxon and other oil companies for the cost of infrastructure projects meant to mitigate the effects of climate change. In dismissing the case, Judge William Alsup reprimanded the cities for attempting to conscript the courts into making policy. It is not the role of the courts, Judge Alsup wrote, to “balance the social utility against the gravity of the anticipated harm.”

Nor is it the role of unelected judges to engineer a massive redistribution of wealth from the private sector to the public sector.

The Trump administration has, indeed, taken some important steps toward combating the opioid-abuse crisis. But, like most government litigation against unpopular legal products, Mr. Trump’s proposed civil suit against Big Pharma is nothing more than an opportunistic money grab and an attempt to regulate the private sector through the back door.

IN THE NEWS: ‘Trump Slams Justice Department’

Most Popular


Put Up or Shut Up on These Accusations, Hillary

Look, one 2016 candidate being prone to wild and baseless accusations is enough. Appearing on Obama campaign manager David Plouffe’s podcast, Hillary Clinton suggested that 2016 Green Party candidate Jill Stein was a “Russian asset,” that Republicans and Russians were promoting the Green Party, and ... Read More
Politics & Policy

Elizabeth Warren Is Not Honest

If you want to run for office, political consultants will hammer away at one point: Tell stories. People respond to stories. We’ve been a story-telling species since our fur-clad ancestors gathered around campfires. Don’t cite statistics. No one can remember statistics. Make it human. Make it relatable. ... Read More
National Review


Today is my last day at National Review. It's an incredibly bittersweet moment. While I've only worked full-time since May, 2015, I've contributed posts and pieces for over fifteen years. NR was the first national platform to publish my work, and now -- thousands of posts and more than a million words later -- I ... Read More

Feminists Have Turned on Pornography

Since the sexual revolution of the 1960s, the feminist movement has sought to condemn traditional sexual ethics as repressive, misogynistic, and intolerant. As the 2010s come to a close, it might be fair to say that mainstream culture has reached the logical endpoint of this philosophy. Whereas older Americans ... Read More
Economy & Business

Andrew Yang, Snake Oil Salesman

Andrew Yang, the tech entrepreneur and gadfly, has definitely cleared the bar for a successful cause candidate. Not only has he exceeded expectations for his polling and fundraising, not only has he developed a cult following, not only has he got people talking about his signature idea, the universal basic ... Read More
White House

The Impeachment Defense That Doesn’t Work

If we’ve learned anything from the last couple of weeks, it’s that the “perfect phone call” defense of Trump and Ukraine doesn’t work. As Andy and I discussed on his podcast this week, the “perfect” defense allows the Democrats to score easy points by establishing that people in the administration ... Read More

Democrats Think They Can Win without You

A  few days ago, Ericka Anderson, an old friend of National Review, popped up in the pages of the New York Times lamenting that “the Democratic presidential field neglects abundant pools of potential Democrat converts, leaving persuadable audiences — like independents and Trump-averse, anti-abortion ... Read More
PC Culture

Defiant Dave Chappelle

When Dave Chappelle’s Netflix special Sticks & Stones came out in August, the overwhelming response from critics was that it was offensive, unacceptable garbage. Inkoo Kang of Slate declared that Chappelle’s “jokes make you wince.” Garrett Martin, in the online magazine Paste, maintained that the ... Read More